title: IPLA2 mRNA expression by human neutrophils in type 2 diabetes and chronic periodontitis.
abstract: Type 2 diabetes mellitus (T2D) is becoming increasingly prevalent worldwide and complications of T2D cause significant systemic and dental morbidity in the susceptible individual. Although T2D has been linked as a significant risk factor for chronic periodontitis (CP), molecular mechanisms explaining the pathogenesis and inflammatory impact of CP in T2D are lacking. iPLA2 is the calcium-independent form of phospholipase A2. In previous studies, we demonstrated that iPLA2 enzyme activity is altered in T2D. The purpose of this study was to elucidate the level of the iPLA2 abnormality in T2D by measuring messenger RNA levels in T2D-associated CP. A total of 53 healthy and T2D subjects with CP were recruited for this study. The clinical periodontal exam included probing pocket depth, clinical attachment levels and bleeding on probing. Peripheral venous blood was collected and neutrophils were isolated. Real time polymerase chain reaction was used to quantify iPLA2 mRNA in neutrophils from healthy controls and people with diabetes. Results revealed that the prevalence of moderate to severe CP was increased in people with T2D. The iPLA, mRNA levels in diabetics with different severity of CP were not significantly different compared to healthy controls; 1.07 vs 0.97 (mild CP), 1.07 vs 0.85 (moderate CP) and 1.07 vs 1.05 (severe CP). Collectively, the data suggest that levels of iPLA2 mRNA in T2D are not different than in health and are not directly influenced by periodontal disease status. The impact of inflammation on iPLA2 regulation is at the level of activation of the enzyme rather than expression at the mRNA level.
authors: Srinivas
authors: S
authors: Ayilavarapu
authors: Alpdogan
authors: A
authors: Kantarci
authors: Hatice
authors: H
authors: Hasturk
authors: Thomas E
authors: TE
authors: Van Dyke
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D055113:Chronic Periodontitis / Q000097:blood / Q000145:classification / Q000201:enzymology*; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000201:enzymology*; D004789:Enzyme Activation; D005260:Female; D005884:Gingival Hemorrhage / Q000145:classification / Q000201:enzymology; D054522:Group VI Phospholipases A2 / Q000032:analysis* / Q000235:genetics; D006801:Humans; D008297:Male; D009504:Neutrophils / Q000201:enzymology*; D017622:Periodontal Attachment Loss / Q000145:classification / Q000201:enzymology; D010514:Periodontal Pocket / Q000145:classification / Q000201:enzymology; D012333:RNA, Messenger / Q000032:analysis*; D060888:Real-Time Polymerase Chain Reaction / Q000379:methods
chemical_list: D012333:RNA, Messenger; D054522:Group VI Phospholipases A2; C516475:PLA2G6 protein, human
references: Ann Periodontol. 1999 Dec;4(1):1-6
references: 10863370
references: Community Dent Oral Epidemiol. 2002 Jun;30(3):182-92
references: 12000341
references: Diabetes Care. 2004 Jan;27 Suppl 1:S5-S10
references: 14693921
references: FASEB J. 2004 Mar;18(3):489-98
references: 15003994
references: Am J Physiol Cell Physiol. 2011 Mar;300(3):C542-9
references: 21178110
references: PLoS One. 2011;6(9):e24422
references: 21935407
references: Atherosclerosis. 2012 May;222(1):196-201
references: 22440543
references: J Dent Res. 2012 Oct;91(10):914-20
references: 22935673
references: J Periodontol. 2013 Apr;84(4 Suppl):S113-34
references: 23631573
references: Contemp Clin Trials. 2013 Nov;36(2):515-26
references: 24080100
references: J Leukoc Biol. 2005 Oct;78(4):862-70
references: 16081595
references: Biochem J. 1994 Jan 1;297 ( Pt 1):217-23
references: 8280102
references: J Immunol. 2006 Nov 15;177(10):7250-6
references: 17082643
references: J Leukoc Biol. 2007 Feb;81(2):520-7
references: 17095613
references: J Immunol. 2007 Jul 1;179(1):647-54
references: 17579087
references: J Immunol. 2007 Nov 15;179(10):7021-9
references: 17982093
references: Oral Dis. 2008 Apr;14(3):191-203
references: 18336370
references: J Leukoc Biol. 2008 Jul;84(1):292-301
references: 18390927
references: Curr Drug Targets. 2008 Aug;9(8):683-97
references: 18691015
references: Respir Physiol Neurobiol. 2009 Feb 28;165(2-3):167-74
references: 19059366
references: J Immunol. 2010 Feb 1;184(3):1507-15
references: 20053941